Dr. Robb S. Friedman, M.D.
Hematology & Oncology (Hematology & Oncology Physician)
- Medicare participating
At a glance
- Medical school
- Georgetown University School of Medicine (1997)
- Years since graduation
- 29
- In the NPI registry since
- 2006
- Medicare patients seen, 2024
- 496
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 1997Medical school: Georgetown University School of Medicine
- 2006Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Hematology & Oncology Physician primary
MA license 221819
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- Brigham and Women's Hospital Boston, MA
- Newton-Wellesley Hospital Newton, MA
- South Shore Hospital South Weymouth, MA
Medical groups
- Dana-Farber Cancer Institute, Inc. (684 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 496
- Services billed
- 801
- Patients’ average age
- 77
| Service | Times | Patients |
|---|---|---|
| Established patient office or other outpatient visit, 30-39 minutes | 878 | 410 |
| Subsequent hospital care with straightforward or low level of medical decision making, per day, if using time, at least 25 minutes | 119 | 36 |
| Established patient office or other outpatient visit, 20-29 minutes | 48 | 38 |
| Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | 35 | 25 |
| Initial hospital care with straightforward or low-level medical decision making, if using time, at least 55 minutes | 21 | 21 |
| Established patient office or other outpatient visit, 40-54 minutes | 15 | 14 |
| Initial hospital care with straightforward or low level of medical decision making, per day, if using time, at least 40 minutes | 11 | 11 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Hydroxyurea Other prescribers in Boston, MA | 113 |
| Brukinsa (zanubrutinib) | 76 |
| Eliquis (apixaban) Other prescribers in Boston, MA | 43 |
| Acyclovir Other prescribers in Boston, MA | 35 |
| Lorazepam Other prescribers in Boston, MA | 22 |
| Revlimid (lenalidomide) | 21 |
| Prednisone Other prescribers in Boston, MA | 21 |
| Jakafi (ruxolitinib phosphate) | 21 |
| Gabapentin Other prescribers in Boston, MA | 14 |
| Omeprazole Other prescribers in Boston, MA | 11 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 16 companies reported 59 payments worth $37,447 in total to this clinician.
| Genmab U.S., Inc. | $9,077 |
|---|---|
| Legend Biotech USA Inc. | $7,930 |
| Beone Medicines USA, Inc. | $3,765 |
| Acrotech Biopharma Inc. | $3,460 |
| Janssen Biotech, Inc. | $3,459 |
| AbbVie Inc. | $2,551 |
| Incyte Corporation | $2,184 |
| Pfizer Inc. | $2,100 |
| Consulting Fee | $32,790 |
|---|---|
| Travel and Lodging | $2,851 |
| Food and Beverage | $1,763 |
| Education | $43.25 |
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| Legend Biotech USA Inc. Apr 3, 2025 | Consulting Fee | $7,930 |
| Beone Medicines USA, Inc. Aug 11, 2025 | Consulting Fee BRUKINSA · Oncology | $3,600 |
| Genmab U.S., Inc. Jun 13, 2025 | Consulting Fee Epkinly · Oncology | $3,191 |
| Genmab U.S., Inc. Dec 18, 2025 | Consulting Fee Epkinly · Oncology | $2,870 |
| Pfizer Inc. Nov 10, 2025 | Consulting Fee ELREXFIO · ONCOLOGY | $2,100 |
| Acrotech Biopharma Inc. Nov 21, 2025 | Consulting Fee BELEODAQ · ONCOLOGY | $2,000 |
| AbbVie Inc. Jan 31, 2025 | Consulting Fee | $1,800 |
| Incyte Corporation Dec 18, 2025 | Consulting Fee | $1,650 |
| Takeda Pharmaceuticals U.S.A., Inc. Nov 12, 2025 | Consulting Fee NINLARO · ONCOLOGY | $1,250 |
| Novartis Pharmaceuticals Corporation Jan 14, 2025 | Consulting Fee SCEMBLIX · Oncology | $1,100 |
All 33 payments other than meals, newest first
| Company | What it was for | Amount |
|---|---|---|
| Genmab U.S., Inc. Dec 18, 2025 | Consulting Fee Epkinly · Oncology | $2,870 |
| Incyte Corporation Dec 18, 2025 | Consulting Fee | $1,650 |
| Incyte Corporation Dec 4, 2025 | Travel and Lodging travel to Orlando, FL | $334 |
| Incyte Corporation Dec 4, 2025 | Travel and Lodging travel to Orlando, FL | $30.28 |
| Janssen Biotech, Inc. Dec 1, 2025 | Consulting Fee | $1,080 |
| AstraZeneca Pharmaceuticals LP Nov 25, 2025 | Education ENHERTU · Oncology · in-kind Company’s descriptionJournal Article | $43.25 |
| Acrotech Biopharma Inc. Nov 21, 2025 | Consulting Fee BELEODAQ · ONCOLOGY | $2,000 |
| Acrotech Biopharma Inc. Nov 21, 2025 | Consulting Fee BELEODAQ · ONCOLOGY · in-kind | $293 |
| Acrotech Biopharma Inc. Nov 21, 2025 | Consulting Fee BELEODAQ · ONCOLOGY · in-kind | $70.53 |
| Acrotech Biopharma Inc. Nov 20, 2025 | Consulting Fee BELEODAQ · ONCOLOGY · in-kind | $567 |
| Acrotech Biopharma Inc. Nov 20, 2025 | Consulting Fee BELEODAQ · ONCOLOGY · in-kind | $293 |
| Acrotech Biopharma Inc. Nov 20, 2025 | Consulting Fee BELEODAQ · ONCOLOGY · in-kind | $133 |
| Acrotech Biopharma Inc. Nov 20, 2025 | Consulting Fee BELEODAQ · ONCOLOGY · in-kind | $104 |
| Genmab U.S., Inc. Nov 15, 2025 | Travel and Lodging Epkinly · Oncology · travel to Nashville, TN | $92.00 |
| Genmab U.S., Inc. Nov 15, 2025 | Travel and Lodging Epkinly · Oncology · travel to Nashville, TN | $40.57 |
| Genmab U.S., Inc. Nov 14, 2025 | Travel and Lodging Epkinly · Oncology · travel to Nashville, TN · in-kind | $995 |
| Genmab U.S., Inc. Nov 14, 2025 | Travel and Lodging Epkinly · Oncology · travel to Nashville, TN · in-kind | $363 |
| Genmab U.S., Inc. Nov 14, 2025 | Travel and Lodging Epkinly · Oncology · travel to Nashville, TN | $41.91 |
| Takeda Pharmaceuticals U.S.A., Inc. Nov 12, 2025 | Consulting Fee NINLARO · ONCOLOGY | $1,250 |
| Pfizer Inc. Nov 10, 2025 | Consulting Fee ELREXFIO · ONCOLOGY | $2,100 |
| Beone Medicines USA, Inc. Aug 11, 2025 | Consulting Fee BRUKINSA · Oncology | $3,600 |
| Genmab U.S., Inc. Jun 13, 2025 | Consulting Fee Epkinly · Oncology | $3,191 |
| Janssen Biotech, Inc. Jun 11, 2025 | Consulting Fee DARZALEX; TECVAYLI; TALVEY · Oncology | $440 |
| AbbVie Inc. May 28, 2025 | Consulting Fee VENCLEXTA · ONCOLOGY | $600 |
| Genmab U.S., Inc. May 17, 2025 | Travel and Lodging Epkinly · Oncology · travel to Atlanta, GA | $62.00 |
| Genmab U.S., Inc. May 16, 2025 | Travel and Lodging Epkinly · Oncology · travel to Atlanta, GA · in-kind | $619 |
| Genmab U.S., Inc. May 16, 2025 | Travel and Lodging Epkinly · Oncology · travel to Atlanta, GA · in-kind | $273 |
| Legend Biotech USA Inc. Apr 3, 2025 | Consulting Fee | $7,930 |
| Janssen Biotech, Inc. Feb 26, 2025 | Consulting Fee DARZALEX; TECVAYLI; TALVEY · Oncology | $469 |
| AbbVie Inc. Jan 31, 2025 | Consulting Fee | $1,800 |
| Janssen Biotech, Inc. Jan 31, 2025 | Consulting Fee DARZALEX; TECVAYLI; TALVEY · Oncology | $625 |
| Novartis Pharmaceuticals Corporation Jan 14, 2025 | Consulting Fee SCEMBLIX · Oncology | $1,100 |
| Janssen Biotech, Inc. Jan 14, 2025 | Consulting Fee DARZALEX; TECVAYLI; TALVEY · Oncology | $625 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.